- Home
- LGND vs CZR Comparison
LGND vs CZR Comparison
Compare LGND & CZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LGND | CZR |
|---|---|---|
| Founded | 1987 | 1937 |
| Country | United States | United States |
| Employees | N/A | 15500 |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.0B |
| IPO Year | 1997 | 2015 |
Fundamental Metrics
Financial Performance| Metric | LGND | CZR |
|---|---|---|
| Price | $316.86 | $29.30 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 15 |
| Target Price | ★ $361.27 | $31.27 |
| AVG Volume (30 Days) | 185.1K | ★ 6.2M |
| Earning Date | 10-29-2026 | 10-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2886.36 | N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | $141,102,000.00 | ★ $1,473,504,000.00 |
| Revenue This Year | $8.82 | $2.86 |
| Revenue Next Year | $31.67 | $2.23 |
| P/E Ratio | $1,019.68 | ★ N/A |
| Revenue Growth | 29.48 | ★ 65.03 |
| 52 Week Low | $175.89 | $17.86 |
| 52 Week High | $326.63 | $30.88 |
Technical Indicators
Market Signals| Indicator | LGND | CZR |
|---|---|---|
| Relative Strength Index (RSI) | 55.75 | 52.36 |
| Support Level | $277.97 | $28.66 |
| Resistance Level | $319.83 | $29.70 |
| Average True Range (ATR) | 11.45 | 0.26 |
| MACD | -0.28 | 0.06 |
| Stochastic Oscillator | 67.94 | 88.96 |
Price Performance
Historical ComparisonAbout LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
About CZR Caesars Entertainment Inc.
Caesars Entertainment's stand-alone portfolio includes about 50 domestic gaming properties across the Las Vegas (48% of 2025 EBITDAR) and regional (49%) markets. Additionally, the company hosts managed properties and digital assets that produced marginal EBITDA in 2025. Caesars' US presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the US portion of William Hill (it sold the international operation in 2022), a digital sports betting platform. The portfolio is set to expand to more than 60 casinos with the proposed acquisition of Caesars by Fertitta Entertainment and its Golden Nugget resorts.